RemeGen Co., Ltd. (HKG:9995)
Hong Kong · Delayed Price · Currency is HKD 88.80
+2.60 (3.02%)
At close: Mar 13, 2026
RemeGen Revenue
In the year 2025, RemeGen had annual revenue of 3.25B CNY with 89.36% growth. RemeGen had revenue of 1.53B in the quarter ending December 31, 2025, with 201.43% growth.
Revenue
3.25B CNY
Revenue Growth
+89.36%
P/S Ratio
17.43
Revenue / Employee
1.06M CNY
Employees
3,070
Market Cap
63.05B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.25B | 1.53B | 89.36% |
| Dec 31, 2024 | 1.72B | 633.91M | 58.54% |
| Dec 31, 2023 | 1.08B | 310.84M | 40.26% |
| Dec 31, 2022 | 772.11M | -651.79M | -45.78% |
| Dec 31, 2021 | 1.42B | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 33.49B |
| WuXi Biologics | 21.98B |
| Innovent Biologics | 12.52B |
| 3SBio | 9.94B |
| Genscript Biotech | 6.50B |
| Shanghai Henlius Biotech | 6.35B |
| Shanghai Junshi Biosciences | 2.78B |
| Akeso | 2.75B |